Zilucoplan May Decrease Symptoms of Myasthenia Gravis Zilucoplan May Decrease Symptoms of Myasthenia Gravis
The novel self-administered subcutaneous agent is safe and relatively well tolerated in generalized myasthenia gravis, a new phase 2 trial and extension study report.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 15, 2019 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

FDA approves first treatment for children with Lambert-Eaton myasthenic syndrome
The U.S. Food and Drug Administration approved Ruzurgi (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age. This is the first FDA approval of a treatment specifically for pediatric patients with LEMS. (Source: World Pharma News)
Source: World Pharma News - May 9, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA Approves Ruzurgi for Children With Rare Autoimmune Disorder
TUESDAY, May 7, 2019 -- Ruzurgi (amifampridine) tablets are now approved to treat Lambert-Eaton myasthenic syndrome (LEMS) in children aged 6 to 17 years, the U.S. Food and Drug Administration announced yesterday. Ruzurgi is the first treatment to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 7, 2019 Category: Pharmaceuticals Source Type: news

FDA grants Jacobus Pharma approval for rare disease drug
Jacobus Pharmaceutical Co Inc on Monday won U.S. approval for the first drug to treat children with Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder. (Source: Reuters: Health)
Source: Reuters: Health - May 7, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves Ruzurgi (amifampridine) for Children with Lambert-Eaton Myasthenic Syndrome
May 06, 2019 -- The U.S. Food and Drug Administration today approved Ruzurgi (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 years to less than 17 years of age. This is the first FDA approval of a... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 7, 2019 Category: Drugs & Pharmacology Source Type: news

Updates in Parkinson's, Myasthenia Gravis, and Multiple Sclerosis Updates in Parkinson's, Myasthenia Gravis, and Multiple Sclerosis
New studies in neurology: Dr Christoph Diener discusses recent developments in the field.Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 21, 2019 Category: Neurology Tags: Neurology & Neurosurgery Commentary Source Type: news

Coral Gables drug company under fire for drug pricing says patient care is 'top priority'
Coral Gables-based Catalyst Pharmaceuticals said patient care is its "top priority" after Sen. Bernie Sanders, I-Vermont, criticized the firm for its pricing of a medication that treats a rare autoimmune disorder. "Catalyst’s top priority is improving patient care in the [Lambert-Eaton Myasthenic Syndrome] community and potentially elsewhere within the neuromuscular community," Catalyst said in a statement provided to the South Florida Business Journal. "We will respond to Senator Sanders’… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - February 6, 2019 Category: American Health Authors: Ashley Portero Source Type: news

Thymectomy Improves Outcomes in Non-Thymomatous Myasthenia Gravis Thymectomy Improves Outcomes in Non-Thymomatous Myasthenia Gravis
Thymectomy plus prednisone improves outcomes in patients with non-thymomatous myasthenia gravis (MG), compared with prednisone alone, according to results from the two-year extension of the MGTX randomized trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 6, 2019 Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news

Thymectomy & #43; PDN Beneficial for Non-Thymomatous Myasthenia Gravis
WEDNESDAY, Jan. 30, 2019 -- For patients with non-thymomatous myasthenia gravis, thymectomy plus prednisone confers benefits versus prednisone alone at five years, according to a study published online Jan. 25 in The Lancet Neurology. Gil I. Wolfe,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 30, 2019 Category: Pharmaceuticals Source Type: news

When You ’ re Struggling with Self-Loathing in Bipolar Disorder
Many people with bipolar disorder struggle with self-loathing. Maybe the self-loathing starts as the depressive phase does with all sorts of awful thoughts about yourself. Because that’s how depression works: It outright lies, and inflicts pain. You can’t do anything right. You’re an abject failure. You’re also stupid. And worthless, and no one will ever really love you for you. You are not attractive or thin or strong enough. You are weak, and you are an embarrassment. Maybe it happens after a manic or hypomanic episode, because you feel terrible about what you did or said during th...
Source: Psych Central - December 2, 2018 Category: Psychiatry Authors: Margarita Tartakovsky, M.S. Tags: Bipolar Disorders General Self-Esteem Self-Help Autoimmune Disease Bipolar Disorder Mood Disorder Negative Thoughts Self Hatred Self Loathing Source Type: news

FDA OKs First Treatment for Lambert-Eaton Myasthenic Syndrome FDA OKs First Treatment for Lambert-Eaton Myasthenic Syndrome
Amifampridine (Firdapse) is approved for adults with Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder characterized by muscle weakness.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 30, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news

FDA approves first treatment for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder
The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a rare autoimmune disorder that affects the connection between nerves and muscles and causes weakness and other symptoms in affected patients. This is the first FDA approval of a treatment for LEMS. (Source: World Pharma News)
Source: World Pharma News - November 30, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Immune checkpoints could be key to treating autoimmune disease myasthenia gravis
(Kanazawa University) The PD-1 immune checkpoint is essential for self-recognition by the immune system, with disruption of the pathway associated with several autoimmune disorders. However, the involvement of PD-1 and its ligand PD-L1 in muscle-weakening autoimmune disease myasthenia gravis is unclear. Now, researchers at Kanazawa University have linked increased PD-L1 expression in the muscles of myasthenia gravis patients with disease severity and shown that this could ultimately help control the immune response and modulate disease symptoms. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 30, 2018 Category: International Medicine & Public Health Source Type: news

FDA Approves Firdapse for Rare Autoimmune Disorder
First agency - sanctioned treatment for adults with Lambert - Eaton myasthenic syndrome (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 30, 2018 Category: Cancer & Oncology Tags: Neurology, Oncology, Pharmacy, Institutional, Source Type: news

FDA Approves Firdapse for Rare Autoimmune Disorder
THURSDAY, Nov. 29, 2018 -- Firdapse (amifampridine) tablets have been approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton myasthenic syndrome (LEMS). The drug is the first agency-sanctioned treatment for the autoimmune... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 29, 2018 Category: Pharmaceuticals Source Type: news

FDA approves new drug developed by Coral Gables company
The U.S. Food and Drug Administration has approved Firdapse, a new medicine developed by Coral Gables-based Catalyst Pharmaceuticals. The biopharmaceutical company (Nasdaq: CPRX) expects the drug to be commercially available in the first quarter of 2019. It was designed to treat Lambert-Eaton Myasthenic Syndrome, a rare autoimmune disease that causes muscle weakness and fatigue. "The approval of Firdapse is a crowning achieveme nt for our company and an important step forward in our transition into… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 29, 2018 Category: Biotechnology Authors: Emon Reiser Source Type: news

Firdapse (Amifampridine) Approved for Rare Autoimmune Disorder
THURSDAY, Nov. 29, 2018 -- Firdapse (amifampridine) tablets have been approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton myasthenic syndrome (LEMS). It's the first agency-sanctioned treatment for the autoimmune disease... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 29, 2018 Category: General Medicine Source Type: news

FDA Approves Firdapse (amifampridine) for Lambert-Eaton Myasthenic Syndrome
November 28, 2018 -- The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a rare autoimmune disorder that affects the connection... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 29, 2018 Category: Drugs & Pharmacology Source Type: news

FDA approves first treatment for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder
FDA approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a rare autoimmune disorder. This is the first FDA approval of a treatment for LEMS. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 29, 2018 Category: American Health Source Type: news

Catalyst Pharmaceuticals files new drug application with FDA
Catalyst Pharmaceuticals has submitted a new drug application (NDA) to the U.S. Food and Drug Administration, bringing the Coral Gables-based drug maker one step closer to launching Firdapse, a treatment for a rare degenerative neuromuscular disease. Founded in 2002, Catalyst (Nasdaq: CPRX) has been working to develop Firdapse for almost a decade, a common timeline in the highly regulated pharmaceutical industry. Firdapse aims to treats symptoms of Lambert-Eaton myasthenic syndrome, a degenerative… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - March 29, 2018 Category: Health Management Authors: Debora Lima Source Type: news

Catalyst Pharmaceuticals Announces Submission of New Drug Application for Firdapse for Treatment of Lambert-Eaton Myasthenic Syndrome
CORAL GABLES, Fla., March 29, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - March 29, 2018 Category: Drugs & Pharmacology Source Type: news

What is the Besinger Score?
Discussion Myasthenia gravis (MG) is a rare disease in the pediatric population. The incidence depends on the population studied but is estimated at 1-9/1 million/year. It was first described by William Heinrich Erb in 1879. The cause is autoantibodies against components of the post-synaptic membrane of the neuromuscular junction, usually against the acetylcholine binding receptor (AChR). It can occur at any age but is more common in the adult population. Juvenile patients (0-19 years) are divided into prepubertal (12 years) who have disease presentations similar to the adult population. In adults there are 5 grades: ocula...
Source: PediatricEducation.org - February 19, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Pyridostigmine treatment reverses pediatric complications of botulinum toxin therapy
(Medical University of South Carolina) In an article published online ahead of print by The Journal of Pediatrics, physicians at the Medical University of South Carolina report that complications from botox therapy for nerve disorders can be reversed with pyridostigmine, a common treatment for myasthenia gravis. The report is the first such use in pediatric patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 26, 2018 Category: International Medicine & Public Health Source Type: news

FDA Approves Soliris (eculizumab) for the Treatment of Patients with Generalized Myasthenia Gravis (GMG)
NEW HAVEN, Conn.--(BUSINESS WIRE) October 23, 2017 --Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the U.S. Food and Drug Administration (FDA) has approved Soliris (eculizumab) as a treatment for adult patients with generalized... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 24, 2017 Category: Drugs & Pharmacology Source Type: news

Study explains why myasthenia patients relapse after treatment
A new Yale-led study helps explain why some myasthenia gravis (MG) patients relapse after initially responding to a drug called rituximab. (Source: Yale Science and Health News)
Source: Yale Science and Health News - September 7, 2017 Category: Universities & Medical Training Source Type: news

Scientists make first crystal model of under-diagnosed autoimmune disease
(University of Southern California) Doctors are limited in how they can treat patients with myasthenia gravis, an autoimmune disease, to just treating its symptoms. The creation of a crystal model gives scientists new insight into a possible target for drug therapy development. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 12, 2017 Category: Biology Source Type: news

Disease Awareness Months Work, Even If You Don't Wear The Ribbon
June ​is the month for more than 10 disease-related awareness campaigns, including Myasthenia Gravis Awareness Month, National Congenital Cytomegalovirus Awareness Month and National Scleroderma Awareness Month. It also hosts a handful of awareness weeks and days, ranging from Helen Keller Deaf-Blind Awareness Week to World Sickle Cell Day. June’s awareness list is shorter than most, but every month is full of diseases and disorders to take note of. You probably haven’t heard of half of them, and you’re not alone. So what’s the point of an awareness day, week or month? To understand the chall...
Source: Healthy Living - The Huffington Post - June 2, 2017 Category: Consumer Health News Source Type: news

New York Academy of Sciences to host conference on myasthenia gravis & related disorders
(New York Academy of Sciences) From May 15th to 17th the New York Academy of Sciences in partnership with the Myasthenia Gravis Foundation of America will host the 13th International Conference on Myasthenia Gravis and Related Disorders. The conference convenes every five years and is the preeminent gathering of basic scientists and clinical researchers to discuss, disseminate, and highlight the advances and challenges of therapies for myasthenia gravis (MG) and related autoimmune diseases. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 12, 2017 Category: International Medicine & Public Health Source Type: news

Alexion submits application to Japan ’s MHLW to extend Soliris indication to treat gMG
Alexion Pharmaceuticals has submitted an application to extend the indication for Soliris (eculizumab) as a potential treatment for patients with refractory generalised myasthenia gravis (gMG). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 24, 2017 Category: Pharmaceuticals Source Type: news

Catalyst Pharma's Neuromuscular Drug Succeeds in Study Catalyst Pharma's Neuromuscular Drug Succeeds in Study
Catalyst Pharmaceuticals Inc said on Wednesday its experimental drug to treat patients with a severe form of myasthenia gravis (MG), a rare neuromuscular disease, met the main goals of a study.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 16, 2017 Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news

Catalyst Pharmaceuticals reports positive results from MuSK-MG trial of Firdapse to treat MG
Catalyst Pharmaceuticals has reported positive top-line results from the MuSK-MG clinical trial of Firdapse to treat patients with myasthenia gravis (MG). (Source: Drug Development Technology)
Source: Drug Development Technology - March 16, 2017 Category: Pharmaceuticals Source Type: news

Catalyst Pharma's neuromuscular drug succeeds in study
(Reuters) - Catalyst Pharmaceuticals Inc said on Wednesday its experimental drug to treat patients with a severe form of myasthenia gravis (MG), a rare neuromuscular disease, met the main goals of a study. (Source: Reuters: Health)
Source: Reuters: Health - March 15, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

What is in the Differential Diagnosis of Fatigue?
Discussion Fatigue is a subjective feeling of decreased energy, tiredness or feeling of exhaustion. Lethargy is often used synonymously, but lethargy is a state of being drowsiness or sleepy, and implies mental status changes. Both can cause the person to be apathetic or less active. Fatigue is a common state that almost everyone experiences multiple times in his or her lifetime. For most people it is a relatively acute or short-term chronic problem, often with a relatively easily identifiable problem cause, such as inadequate sleep, acute illness, or overexertion. For some, it can be less readily identifiable such as dep...
Source: PediatricEducation.org - January 23, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Myasthenia gravis and its aeromedical implications - Jagathesan T, O'Brien MD.
BACKGROUND: Myasthenia gravis is an autoimmune condition where antibodies form against the acetylcholine receptors at the neuromuscular junction, eventually causing damage to the motor end plate. The clinical features include muscle fatigability as well as... (Source: SafetyLit)
Source: SafetyLit - January 14, 2017 Category: Global & Universal Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Your NEJM Group Today: Myasthenia Gravis, Top Gastroenterology Stories of 2016, Washington State Family Med Opportunities (FREE)
By the Editors NEJM Group offers so many valuable resources for clinicians. Here's what we chose for you today:NEJM Clinical Practice Center: Review article: Myasthenia … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - January 4, 2017 Category: Primary Care Source Type: news

Catalyst begins enrolment for second Phase III LMS-003 trial of Firdapse to treat LEMS
US-based biopharmaceutical company Catalyst has begun enrolment for its second Phase III LMS-003 clinical trial of Firdapse to treat Lambert-Eaton myasthenic syndrome (LEMS). (Source: Drug Development Technology)
Source: Drug Development Technology - December 19, 2016 Category: Pharmaceuticals Source Type: news

Rituximab Effective, Durable in Refractory Myasthenia Gravis Rituximab Effective, Durable in Refractory Myasthenia Gravis
Dr Laurie Barclay discusses results from a small study and what they may mean for incorporating rituximab in the treatment of myasthenia gravis.Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - December 12, 2016 Category: Neurology Tags: Neurology & Neurosurgery Viewpoint Source Type: news

Catalyst Pharmaceuticals Provides Update on its Clinical Trial for Patients with Congenital Myasthenic Syndromes
CORAL GABLES, Fla., Dec. 08, 2016 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases,... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 8, 2016 Category: Drugs & Pharmacology Source Type: news

Your NEJM Group Today: Ice-Pack Test for Myasthenia Gravis, Childhood BMI & Later Psychosocial Health, Massachusetts Urgent Care Opportunities (FREE)
By the Editors NEJM Group offers so many valuable resources for practicing clinicians. Here's what we chose for you today:NEJM Clinical Practice Center: Image in Clinical Medicine: … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 14, 2016 Category: Primary Care Source Type: news

FDA approval brings biopharma firm one step closer to lucrative pharmaceutical submarket
Shares of Catalyst Pharmaceuticals (Nasdaq: CPRX) jumped more than 12 percent Friday following announcement of the U.S. Food and Drug Administration's stamp of approval on its latest drug. A medicine created by the Coral Gables-based company called Firdapse earned “orphan” status, a designation for drugs that safely and effectively treat or prevent rare diseases. Firdapse aims to treat a portion of the 100,000 Americans who suffer of myasthenia gravis, a degenerative neuromuscu lar disease that… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 2, 2016 Category: Pharmaceuticals Authors: Debora Lima Source Type: news

Surgery Effective for Muscle-Weakening Disorder
Myasthenia gravis affects 60,000 Americans, but removal of thymus gland appears to help, research shows (Source: WebMD Health)
Source: WebMD Health - August 11, 2016 Category: Consumer Health News Source Type: news

Surgery Effective Against Immune Disorder That Weakens Muscles
Myasthenia gravis affects 60,000 Americans, but removal of thymus gland appears to help, research shows Source: HealthDay Related MedlinePlus Page: Myasthenia Gravis (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - August 11, 2016 Category: Consumer Health News Source Type: news

Thymectomy Bests Medical Therapy in Myasthenia Gravis Thymectomy Bests Medical Therapy in Myasthenia Gravis
' The trial ends an 80-year controversy'about benefits of thymectomy for patients with major myasthenia gravis but no thymus tumor, experts say.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 11, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

NIH-funded study supports surgery as treatment for myasthenia gravis
Autoimmune disease causes muscle weakness and fatigue. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - August 11, 2016 Category: American Health Source Type: news

Surgery Effective Against Immune Disorder That Weakens Muscles
THURSDAY, Aug. 11, 2016 -- Removing the thymus gland is an effective treatment for myasthenia gravis, an autoimmune disorder that causes life-threatening muscle weakness, researchers report. Since the 1940s, doctors have been surgically removing... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 11, 2016 Category: Journals (General) Source Type: news

Thymectomy improves clinical outcomes for myasthenia gravis
Thymectomy improved 3-year clinical outcomes and proved superior to medical therapy for mild to severe nonthymomatous myasthenia gravis, according to a report published online Aug. 11 in the New... (Source: Family Practice News)
Source: Family Practice News - August 10, 2016 Category: Primary Care Source Type: news

NIH-funded study supports surgery as treatment for myasthenia gravis
In a global study of myasthenia gravis, an autoimmune disease that causes muscle weakness and fatigue, researchers found that surgical removal of an organ called the thymus reduced patients ’ weakness, and their need for immunosuppressive drugs. The study, published in the New England Journal of Medicine, was partially funded by the National Institutes of Health. (Source: NINDS Press Releases and News: National Institute of Neurological Disorders and Stroke)
Source: NINDS Press Releases and News: National Institute of Neurological Disorders and Stroke - August 10, 2016 Category: Neurology Source Type: news

New Consensus Guidance on Myasthenia Gravis New Consensus Guidance on Myasthenia Gravis
The new international expert consensus is intended to be a guide for clinicians caring for patients with myasthenia gravis worldwide. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - July 12, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Success With Stem Cell Transplant in Myasthenia Gravis Success With Stem Cell Transplant in Myasthenia Gravis
Seven patients with severe myasthenia gravis who received autologous hematopoietic stem cell transplants have experienced long-term remission. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 4, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

What it’s like to be in neurology: Shadowing Dr. Govindarajan
As a medical student, do you ever wonder what it’s like to be a neurologist? Here’s your chance to find out. Meet Raghav Govindarajan, MD, a neurologist and featured physician in AMA Wire’s® “Shadow Me” Specialty Series, which offers advice directly from physicians about life in their specialties. Read his insights to help determine whether a career in neurology might be a good fit for you. "Shadowing" Dr. Govindarajan Specialty: Neurology Practice setting: University hospital Years in practice: 2 A typical week in my practice: I am a neurologist with special...
Source: AMA Wire - April 19, 2016 Category: Journals (General) Authors: Amy Farouk Source Type: news